Thermo Fisher Scientific Inc. (TMO) continues to demonstrate strong stock performance, boosted by impressive Q4 earnings with an $11.4B revenue driven by new product growth. Several investment firms, including WH Cornerstone Investments Inc. and Root Financial Partners LLC, have increased their shares in the company, while others like Chevy Chase Trust Holdings and Valley Brook Capital Group Inc trimmed their holdings. Notably, Coho Partners ranks TMO as its 6th largest position. The company saw a brief drop in trading, down by 3.9%, but ti has made a comeback buoyed by a robust Q4 earnings report that surpassed expectations. Thermo Fisher is setting new goals, including a 100% renewable electricity target via a solar power agreement with X-ELIO. The company recently successfully completed a $1B share repurchase and authorized another $4B share repurchase, signalling market confidence. Utilizing advanced sequencing technology, the company is poised to advance myeloid cancer clinical research. Also noteworthy is Thermo Fisher's Olink platform being selected for the world's largest human proteome study.
Thermo Fisher Scientific TMO News Analytics from Thu, 11 Jul 2024 07:00:00 GMT to Sat, 15 Feb 2025 13:15:28 GMT -
Rating 7
- Innovation 8
- Information 8
- Rumor -3
